Clinical and immunological characteristics of patients with chronic hepatitis C during antiviral therapy in interferon-free regimen

Cover Page

Cite item

Full Text

Abstract

Aim. To study the biomarkers of liver inflammation that occur during antiviral therapy in the interferon-free regimen.

Methods. 14 patients were examined during antiviral therapy of chronic viral hepatitis C genotype 1. Treatment with dasabuvir, ombitasvir, paritaprevir and ritonavir for 12 weeks was received by 8 patients. Daklatasvir and asunaprevir was administered to 6 patients for 24 weeks. 11 patients had the concentrations of cytokines/chemokines (TNFα, CCL2/MCP-1, CCL20/MIP-3α, CXCL9/MIG, CXCL10/IP-10, CXCL11/ITAC) measured in the blood plasma by multiplex analysis. In six patients, the content of CXCR3+ and CCR6+ receptors in different subpopulations of lymphocytes was determined by flow cytofluorimetry. Patients were divided into 2 groups: without liver fibrosis and with severe fibrosis.

Results. 100% demonstrated virologic response. In both groups, significant reduction of CXCL10/IP-10 concentration was found in the patients at the end of treatment compared to pre-therapy (p=0.025 and 0.00015, respectively). In the first group a tendency to increase of the relative content of T-lymphocytes (p=0.065) was observed, and in the second group, a significant increase of the relative content of TNKCCR6+ (p=0.02) was observed.

Conclusion. Chemokine CXCL10/IP-10 is a biomarker characterizing the decrease of liver inflammation during therapy and not depending on the degree of liver fibrosis. The tendency to increase of the relative content of T lymphocytes in the first group and a significant increase in TNKCCR6+ cells during treatment in the second group may play an important role in eliminating hepatitis C virus.

About the authors

V V Basina

Saint Petersburg State Pediatric Medical University

Author for correspondence.
Email: v.basina@mail.ru
Saint-Petersburg, Russia

A A Sukhoruk

Saint Petersburg State Pediatric Medical University; Saint-Petersburg Pasteur Research Institute of Epidemiology and Mictobiology

Email: v.basina@mail.ru
Saint-Petersburg, Russia; Saint-Petersburg, Russia

N A Arsentieva

Saint-Petersburg Pasteur Research Institute of Epidemiology and Mictobiology

Email: v.basina@mail.ru
Saint-Petersburg, Russia

N E Lyubimova

Saint-Petersburg Pasteur Research Institute of Epidemiology and Mictobiology

Email: v.basina@mail.ru
Saint-Petersburg, Russia

A V Semenov

Saint-Petersburg Pasteur Research Institute of Epidemiology and Mictobiology

Email: v.basina@mail.ru
Saint-Petersburg, Russia

E V Esaulenko

Saint Petersburg State Pediatric Medical University; Saint-Petersburg Pasteur Research Institute of Epidemiology and Mictobiology

Email: v.basina@mail.ru
Saint-Petersburg, Russia; Saint-Petersburg, Russia

A A Totolyan

Saint-Petersburg Pasteur Research Institute of Epidemiology and Mictobiology

Email: v.basina@mail.ru
Saint-Petersburg, Russia

References

  1. World Health Organization. Hepatitis C. Key facts. http://www.who.int/news-room/fact-sheets/detail/hepatitis-c (access date: 18.06.18).
  2. Angeli P., Bernardi M., Villanueva C. et al. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of patients with decompensated cirrhosis. J. Hepatol. 2018; 69 (2): 406–460. doi: 10.1016/j.jhep.2018.03.024.
  3. Esaulenko E.V., Vysochinskaya V.V., Nikitina O.E. The effectiveness of combined antiviral therapy in patients with chronic hepatitis C, 1B genotype with various degrees of fibrosis. Zhurnal infektologii. 2012; 4 (3S): 75. (In Russ.)
  4. Maevskaya M.V., Ivashkin V.T., Znojko O.O. at el. Efficacy and safety of the national inhibitor of Narlaprevir protease in primary and previously treated patients with chronic hepatitis C caused by the 1st genotype virus, without liver cirrhosis (results of the Pioneer study). Rossijskij zhurnal gastroehnterologii, gepatologii, koloproktologii. 2017; 27 (6): 41–51 (In Russ.)
  5. Ivashkin V.T., Maevskaya M.V., Аbdurakhmanov D.T. et al. Modern possibilities of antiviral therapy using Daclatasvir in the treatment of patients with chronic viral hepatitis C: results of the individual access program. Rossijskij zhurnal gastroehnterologii, gepatologii, koloprotologii. 2017; 27 (6): 52–62. (In Russ.)
  6. Lin J.C., Habersetzer F., Rodriguez-Torres M. et al. Interferon γ-induced protein 10 kinetics in treatment-naive versus treatment-experienced patients receiving interferon-free therapy for hepatitis C virus infection: implications for the innate immune response. J. Infect. Dis. 2014; 210 (12): 881–885. doi: 10.1093/infdis/jiu325.
  7. Bility M.T., Nio K., Li F. et al. Chronic hepatitis C infection-induced liver fibrogenesis is associated with M2 macrophage activation. Sci. Rep. 2016; (6): 39520. doi: 10.1038/srep39520.
  8. Kazankov K., Barrera F., Moller H.J. et al. Soluble CD163, a macrophage activation marker, is independently associated with fibrosis in patients with chronic viral hepatitis B and C. Hepatology. 2014; 60 (2): 521–530. doi: 10.1002/hep.27129.
  9. Sandler N.G., Koh C., Roque A. et al. Host response to translocated microbial products predicts outcomes of patients with HBV or HCV infection. Gastroenterology. 2011; 141 (4): 1220–1230. doi: 10.1053/j.gastro.2011.06.063.
  10. Askarieh G., Alsio A., Pugnale P. et al. Systemic and intrahepatic interferon-gamma-inducible protein 10 kDa predicts the first-phase decline in hepatitis C virus RNA and overall viral response to therapy in chronic hepatitis C. Hepatology. 2010; 51: 1523–1530. doi: 10.1002/hep.23509.
  11. Prinapori R., Sticchi L., Alicino C. et al. Role of HCV-RNA decay and IP-10 levels after 48 hours of standard HCV therapy as predictors of rapid virological response. Clin. Res. Hepatol. Gastroenterol. 2015; 39: 705–710. doi: 10.1016/j.clinre.2015.04.001.
  12. Mascia C., Vita S., Zuccalà P. et al. Changes in inflammatory biomarkers in HCV infected patients undergoing direct acting antiviral-containing regimens with or without interferon. PLoS ONE. 2017; 12 (6): e0179400. doi: 10.1371/journal.pone.0179400.
  13. Serti E., Chepa-Lotrea X., Kim Y. J. et al. Successful Interferon-Free Therapy of Chronic Hepatitis C Virus Infection Normalizes Natural Killer Cell Function. Gastroenterology. 2015; 149 (1): 190–200. doi: 10.1053/j.gastro.2015.03.004.
  14. Diago C. M., Castellano G., GarcoAa-Samaniego J. et al. Association of pretreatment serum interferon gamma inducible protein 10 levels with sustained virological response to peginterferon plus ribavirin therapy in genotype 1 infected patients with chronic hepatitis. Gut. 2006; 55 (3): 374–379. doi: 10.1136/gut.2005.074062.

© 2018 Basina V.V., Sukhoruk A.A., Arsentieva N.A., Lyubimova N.E., Semenov A.V., Esaulenko E.V., Totolyan A.A.

Creative Commons License

This work is licensed
under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.




This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies